The $1,000 genome won't do any good for science if researchers can't interpret it, says Adina Mangubat, CEO of Spiral Genetics, in Xconomy. While industry has focused most of its time and energy to creating better ways to sequence a genome, it has "largely ignored the computational power required to extract and analyze the genomic data in a timeframe that keeps it relevant," Mangubat adds. And most labs aren't prepared for all that data.